keyword
MENU ▼
Read by QxMD icon Read
search

Pneumococcal vaccine in adults

keyword
https://www.readbyqxmd.com/read/27895845/a-trial-of-a-7-valent-pneumococcal-conjugate-vaccine-in-hiv-infected-adults
#1
Neil French, Stephen B Gordon, Thandie Mwalukomo, Sarah A White, Gershom Mwafulirwa, Herbert Longwe, Martin Mwaiponya, Eduard E Zijlstra, Malcolm E Molyneux, Charles F Gilks
BACKGROUND: Streptococcus pneumoniae is a leading and serious coinfection in adults with human immunodeficiency virus (HIV) infection, particularly in Africa. Prevention of this disease by vaccination with the current 23-valent polysaccharide vaccine is suboptimal. Protein conjugate vaccines offer a further option for protection, but data on their clinical efficacy in adults are needed. METHODS: In this double-blind, randomized, placebo-controlled clinical efficacy trial, we studied the efficacy of a 7-valent conjugate pneumococcal vaccine in predominantly HIV-infected Malawian adolescents and adults who had recovered from documented invasive pneumococcal disease...
September 2016: Malawi Medical Journal: the Journal of Medical Association of Malawi
https://www.readbyqxmd.com/read/27885841/the-utility-of-saliva-for-the-assessment-of-anti-pneumococcal-antibodies-investigation-of-saliva-as-a-marker-of-antibody-status-in-serum
#2
Jennifer L J Heaney, Anna C Phillips, Douglas Carroll, Mark T Drayson
CONTEXT: Salivary antibodies may act as non-invasive marker of systemic immunity enabling assessment of vaccination and protection against bacterial infections. OBJECTIVE: To assess if levels of anti-pneumococcal antibodies in saliva reflect concentrations in serum and determine whether saliva can accurately identify protective concentrations in serum. METHODS: IgG, IgA and IgM antibody levels in paired saliva and serum samples were measured against 12 pneumococcal polysaccharide antigens in 72 healthy adults...
November 25, 2016: Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
https://www.readbyqxmd.com/read/27869440/immunology-update-new-vaccines
#3
S Paul Starr
A new 9-valent human papillomavirus (HPV) vaccine is effective against more cancer-causing HPV types than previous vaccines. HPV vaccine series started with previous vaccines can be completed with the 9-valent vaccine. Two new influenza vaccines are available for adults 65 years and older: a high-dose vaccine and an enhanced adjuvant vaccine. These elicit stronger antibody responses than standard-dose vaccines. Current guidelines specify no preference for the new versus standard-dose vaccines. Two new group B meningococcal vaccines are intended for use during outbreaks and for patients with asplenia, complement deficiencies, frequent occupational meningococcus exposure, or for patients who desire protection from type B meningococcus...
November 2016: FP Essentials
https://www.readbyqxmd.com/read/27867073/immune-status-assessment-in-adult-lung-transplant-candidates
#4
Diana A van Kessel, Thijs W Hoffman, Heleen van Velzen-Blad, Ed A van de Graaf, Jan C Grutters, Ger T Rijkers
BACKGROUND: Lung transplant recipients have an increased susceptibility to a variety of infections due to immunosuppressive therapy. Current guidelines recommend pneumococcal and other vaccinations, prior to lung transplantation to protect against post-transplant infections, but measurement of the antibody response to vaccination is not advised. Immune status investigation in lung transplant candidates, including the response to pneumococcal polysaccharide vaccination, has not been described...
November 17, 2016: Transplant Immunology
https://www.readbyqxmd.com/read/27861340/prognostic-factors-associated-with-mortality-and-major-in-hospital-complications-in-patients-with-bacteremic-pneumococcal-pneumonia-population-based-study
#5
Jessica A Beatty, Sumit R Majumdar, Gregory J Tyrrell, Thomas J Marrie, Dean T Eurich
Bacteremic pneumococcal pneumonia (BPP) causes considerable mortality and morbidity. We aimed to identify prognostic factors associated with mortality and major in-hospital complications in BPP.A prospective, population-based clinical registry of 1636 hospitalized adult patients (≥18 years) with BPP was established between 2000 and 2010 in Northern Alberta, Canada. Prognostic factors for mortality and major in-hospital complications (e.g., cardiac events, mechanical ventilation, aspiration) were evaluated using multivariable logistic regression...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27855182/a-non-human-primate-model-of-severe-pneumococcal-pneumonia
#6
Luis F Reyes, Marcos I Restrepo, Cecilia A Hinojosa, Nilam J Soni, Anukul T Shenoy, Ryan P Gilley, Norberto Gonzalez-Juarbe, Julio R Noda, Vicki T Winter, Melissa A de la Garza, Robert E Shade, Jacqueline J Coalson, Luis D Giavedoni, Antonio Anzueto, Carlos J Orihuela
RATIONALE: Streptococcus pneumoniae is the leading cause of community-acquired pneumonia and infectious death in adults worldwide. A non-human primate model is needed to study the molecular mechanisms that underlie the development of severe pneumonia, identify diagnostic tools, explore potential therapeutic targets, and test clinical interventions during pneumococcal pneumonia. OBJECTIVE: To develop a non-human primate model of pneumococcal pneumonia. METHODS: Seven adult baboons (Papio cynocephalus) were surgically tethered to a continuous monitoring system that recorded heart rate, temperature, and electrocardiography...
2016: PloS One
https://www.readbyqxmd.com/read/27847374/multiplex-urinary-antigen-detection-for-13-streptococcus-pneumoniae-serotypes-improves-diagnosis-of-pneumococcal-pneumonia-in-south-african-hiv-infected-adults
#7
Werner C Albrich, Michael W Pride, Shabir A Madhi, Jan Callahan, Peter V Adrian, Roger French, Nadia van Niekerk, Shite Sebastian, Victor Souza, Jean-Noel Telles, Glaucia Paranhos-Baccalà, Kathrin U Jansen, Keith P Klugman
BACKGROUND: A serotype-specific urinary antigen detection assay (UAD) for 13 serotypes included in the pneumococcal conjugate vaccine (PCV13) was recently reported as a useful diagnostic tool for pneumococcal pneumonia. We aimed to assess the diagnostic accuracy of the UAD in HIV-infected South African adults. METHODS: Urine specimens from a well-defined cohort of HIV-infected South African adults with pneumonia were evaluated retrospectively in the UAD assay. Pneumonia was considered pneumococcal if either sputum Gram stain, sputum culture, blood culture or immunochromatographic (ICT) BinaxNow® S...
November 9, 2016: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/27844262/changes-in-the-pneumococcal-disease-related-hospitalisations-in-spain-after-the-replacement-of-7-valent-by-13-valent-conjugate-vaccine
#8
L Georgalis, A Mozalevskis, M V Martínez de Aragón, M Garrido-Estepa
In Spain, anti-pneumococcal vaccination is recommended for all children under 2 years old, high-risk groups and adults ≥65 years old. However, it is not funded in most autonomous communities. This study aims to compare pneumococcal disease hospitalisation rates between Period 1 (2007-2009), when 7-valent (PCV7) vaccine was available, and Period 2 (2011-2013), after the change to 13-valent (PCV13) vaccine in Spain. Data on hospitalisations were obtained from the National Registry of Hospitalisations. We calculated hospitalisation rates (HRs) and hospitalisation rate ratios (HRRs) among periods by age group and autonomous community, for all and by clinical presentation...
November 14, 2016: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/27836437/post-licensure-surveillance-of-13-valent-pneumococcal-conjugate-vaccine-pcv13-in-adults-aged-%C3%A2-19years-old-in-the-united-states-vaccine-adverse-event-reporting-system-vaers-june-1-2012-december-31-2015
#9
Penina Haber, Jorge Arana, Tamara Pilishvili, Paige Lewis, Pedro L Moro, Maria Cano
BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) was first recommended for use in adults aged ⩾19years with immunocompromising conditions in June 2012. On August 2014, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of PCV13 among adults aged ⩾65years. METHODS: We assessed adverse events (AEs) reports following PCV13 in adults aged ⩾19years reported to the Vaccine Adverse Event Reporting System (VAERS) from June 2012 to December 2015...
December 7, 2016: Vaccine
https://www.readbyqxmd.com/read/27832151/nationwide-trends-in-bacterial-meningitis-before-the-introduction-of-13-valent-pneumococcal-conjugate-vaccine-burkina-faso-2011-2013
#10
Dinanibè Kambiré, Heidi M Soeters, Rasmata Ouédraogo-Traoré, Isaïe Medah, Lassana Sangare, Issaka Yaméogo, Guetawendé Sawadogo, Abdoul-Salam Ouédraogo, Soumeya Hema-Ouangraoua, Lesley McGee, Velusamy Srinivasan, Flavien Aké, Malika Congo-Ouédraogo, Soufian Sanou, Absatou Ky Ba, Ryan T Novak, Chris Van Beneden
BACKGROUND: Following introduction of Haemophilus influenzae type b vaccine in 2006 and serogroup A meningococcal conjugate vaccine in 2010, Streptococcus pneumoniae (Sp) became the leading cause of bacterial meningitis in Burkina Faso. We describe bacterial meningitis epidemiology, focusing on pneumococcal meningitis, before 13-valent pneumococcal conjugate vaccine (PCV13) introduction in the pediatric routine immunization program in October 2013. METHODS: Nationwide population-based meningitis surveillance collects case-level demographic and clinical information and cerebrospinal fluid (CSF) laboratory results...
2016: PloS One
https://www.readbyqxmd.com/read/27818435/pneumococcal-vaccination-in-low-income-latinos-an-unexpected-trend-in-oregon-community-health-centers
#11
John Heintzman, Steffani R Bailey, Stuart Cowburn, Eve Dexter, Joseph Carroll, Miguel Marino
BACKGROUND: In cross-sectional studies, Latino and Spanish-speaking U.S. residents age 65 and over are less likely to receive pneumococcal vaccination than non-Hispanic Whites. METHODS: We performed a time-to-event, cohort analysis, in 23 Oregon community health centers of low-income patients who turned 65 in the study period (2009-2013; n = 1,248). The outcome measure was receipt of PPSV-23 in the study period by race / ethnicity, preferred language, and insurance status...
2016: Journal of Health Care for the Poor and Underserved
https://www.readbyqxmd.com/read/27790208/serotype-3-remains-the-leading-cause-of-invasive-pneumococcal-disease-in-adults-in-portugal-2012-2014-despite-continued-reductions-in-other-13-valent-conjugate-vaccine-serotypes
#12
Andreia N Horácio, Catarina Silva-Costa, Joana P Lopes, Mário Ramirez, José Melo-Cristino
Since 2010 the 13-valent pneumococcal conjugate vaccine (PCV13) replaced the 7-valent vaccine (PCV7) as the leading pneumococcal vaccine used in children through the private sector. Although, neither of the PCVs were used significantly in adults, changes in adult invasive pneumococcal disease (IPD) were expected due to herd protection. We characterized n = 1163 isolates recovered from IPD in adults in 2012-2014 with the goal of documenting possible changes in serotype prevalence and antimicrobial resistance...
2016: Frontiers in Microbiology
https://www.readbyqxmd.com/read/27780630/effect-of-tdap-when-administered-before-with-or-after-the-13-valent-pneumococcal-conjugate-vaccine-coadministered-with-the-quadrivalent-meningococcal-conjugate-vaccine-in-adults-a-randomised-controlled-trial
#13
M Tashani, M Alfelali, O Barasheed, A S Alqahtani, L Heron, M Wong, H Rashid, R Booy
Sequential or co-administration of vaccines has potential to alter the immune response to any of the antigens. Existing literature suggests that prior immunisation of tetanus/diphtheria-containing vaccines can either enhance or suppress immune response to conjugate pneumococcal or meningococcal vaccines. We examined this interaction among adult Australian travellers before attending the Hajj pilgrimage 2014. We also investigated tolerability of these vaccines separately and concomitantly. We randomly assigned each participant to one of three vaccination schedules...
October 22, 2016: Vaccine
https://www.readbyqxmd.com/read/27780489/risk-assessment-and-laboratory-investigation-of-respiratory-illness-in-travellers-returning-to-singapore-2012-2015-experience-from-the-mers-cov-surveillance-programme
#14
M K Win, A Chow, H J Ho, S Y Tay, Y S Leo
Since the emergence of Middle East respiratory syndrome coronavirus (MERS-CoV), Singapore has enhanced its national surveillance system to detect the potential importation of this novel pathogen. Using the guidelines from the Singapore Ministry of Health, a suspect case was defined as a person with clinical signs and symptoms suggestive of pneumonia or severe respiratory infection with breathlessness, and with an epidemiological link to countries where MERS-CoV cases had been reported within the preceding 14 days...
October 26, 2016: Epidemiology and Infection
https://www.readbyqxmd.com/read/27765456/-pneumococcal-disease-in-adults-risk-levels-and-vaccine-recommendations
#15
Angel Vila-Córcoles, Olga Ochoa-Gondar
There are currently two anti-pneumococcal vaccines available for use in adults: the classical 23-valent polysaccharide pneumococcal vaccine (PPV23) and the new 13-valent pneumococcal conjugate vaccine (PCV13). The main advantage of the PCV13 is the potentially better immunogenicity, with its major disadvantages being the higher cost and the lower serotype-coverage than the PPV23. The currently available scientific evidence supports the following basic recommendations: (i)among adults with greatest risk (basically asplenia and immunocompromised), a dual vaccination (PCV13+PPV23) is recommended; (ii)among adults with increased risk (basically persons >65years-old and patients 15-64years with chronic pulmonary or heart disease, diabetes and/or alcoholism), a single vaccination with PPV23 is recommended (single dose in primo-vaccinated >65years; re-vaccination at 5-10years in those primo-vaccinated <65years-old); and (iii) in the rest of adults (risk normal/low) vaccination is not recommended...
October 17, 2016: Atencion Primaria
https://www.readbyqxmd.com/read/27756499/community-acquired-pneumonia-in-adults-highlighting-missed-opportunities-for-vaccination
#16
Francesco Blasi, Murat Akova, Paolo Bonanni, Nathalie Dartois, Evelyne Sauty, Chris Webber, Antoni Torres
Pneumococcal pneumonia remains a clear unmet medical need for adults worldwide. Despite advances in vaccine technology, vaccination coverage remains low, putting many people at risk of significant morbidity and mortality. The herd effect seen with paediatric vaccination is not enough to protect all older and vulnerable people in the community, and more needs to be done to increase the uptake of pneumococcal vaccination in adults. Several key groups are at increased risk of contracting pneumococcal pneumonia, and eligible patients are being missed in clinical practice...
October 15, 2016: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/27756235/an-outbreak-of-pneumococcal-meningitis-among-older-children-%C3%A2-5%C3%A2-years-and-adults-after-the-implementation-of-an-infant-vaccination-programme-with-the-13-valent-pneumococcal-conjugate-vaccine-in-ghana
#17
Brenda Anna Kwambana-Adams, Franklin Asiedu-Bekoe, Badu Sarkodie, Osei Kuffour Afreh, George Khumalo Kuma, Godfred Owusu-Okyere, Ebenezer Foster-Nyarko, Sally-Ann Ohene, Charles Okot, Archibald Kwame Worwui, Catherine Okoi, Madikay Senghore, Jacob Kweku Otu, Chinelo Ebruke, Richard Bannerman, Kwame Amponsa-Achiano, David Opare, Gemma Kay, Timothy Letsa, Owen Kaluwa, Ebenezer Appiah-Denkyira, Victor Bampoe, Syed M A Zaman, Mark J Pallen, Umberto D'Alessandro, Jason M Mwenda, Martin Antonio
BACKGROUND: An outbreak of pneumococcal meningitis among non-infant children and adults occurred in the Brong-Ahafo region of Ghana between December 2015 and April 2016 despite the recent nationwide implementation of a vaccination programme for infants with the 13-valent pneumococcal conjugate vaccine (PCV13). METHODS: Cerebrospinal fluid (CSF) specimens were collected from patients with suspected meningitis in the Brong-Ahafo region. CSF specimens were subjected to Gram staining, culture and rapid antigen testing...
October 18, 2016: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27755655/using-the-4-pillars-practice-transformation-program-to-increase-pneumococcal-immunizations-for-older-adults-a-cluster-randomized-trial
#18
Richard K Zimmerman, Anthony E Brown, Valory N Pavlik, Krissy K Moehling, Jonathan M Raviotta, Chyongchiou J Lin, Song Zhang, Mary Hawk, Shakala Kyle, Suchita Patel, Faruque Ahmed, Mary Patricia Nowalk
OBJECTIVES: To test the effectiveness of a step-by step, evidence-based guide, the 4 Pillars Practice Transformation Program, to increase adult pneumococcal vaccination. DESIGN: Randomized controlled cluster trial (RCCT) in Year 1 (June 1, 2013 to May 31, 2014) and pre-post study in Year 2 (June 1, 2014 to January 31, 2015) with data analyzed in 2016. Baseline year was June 1, 2012, to May 31, 2013. Demographic and vaccination data were derived from deidentified electronic medical record extractions...
October 18, 2016: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/27749111/invasive-pneumococcal-disease-among-hiv-infected-and-hiv-uninfected-adults-in-a-large-integrated-healthcare-system
#19
Julia L Marcus, Roger Baxter, Wendy A Leyden, Dharushana Muthulingam, Arnold Yee, Michael A Horberg, Daniel B Klein, William J Towner, Chun R Chao, Charles P Quesenberry, Michael J Silverberg
It is unclear whether HIV-infected individuals remain at higher risk of invasive pneumococcal disease (IPD) compared with HIV-uninfected individuals. We conducted a cohort study of HIV-infected and demographically matched HIV-uninfected adults within Kaiser Permanente Northern California during the period 1996-2011. We used Poisson models to obtain rate ratios (RRs) for incident IPD associated with HIV infection and other risk factors. Among 13,079 HIV-infected and 137,643 HIV-uninfected adults, the IPD rate per 100,000 person-years was 160 (n = 109 events) for HIV-infected and 8 (n = 75 events) for HIV-uninfected subjects, with an adjusted RR of 13...
October 2016: AIDS Patient Care and STDs
https://www.readbyqxmd.com/read/27730119/the-epidemiology-of-invasive-pneumococcal-disease-in-older-adults-from-2007-to-2014-in-ontario-canada-a-population-based-study
#20
Shalini Desai, Michelle E Policarpio, Kenney Wong, Jonathan Gubbay, Jill Fediurek, Shelley Deeks
BACKGROUND: In Ontario, pneumococcal conjugate vaccines (PCVs) have been sequentially introduced into the publicly funded childhood vaccination program since 2005. A 23-valent polysaccharide pneumococcal vaccine (PPV23) has been routinely recommended for adults aged 65 years and older since 1996. To determine the effect of herd immunity, we examined the epidemiology of invasive pneumococcal disease in adults aged 65 years and older. METHODS: Invasive pneumococcal disease is a provincially reportable disease...
July 2016: CMAJ Open
keyword
keyword
57998
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"